Healthcare tech company Omnicell (NASDAQ:OMCL) will be reporting earnings this Thursday before market hours. Here's what to expect.
Omnicell beat analysts' revenue expectations last quarter, reporting revenues of $312.2 million, up 7.4% year on year. It was a mixed quarter for the company, with a beat of analysts' EPS estimates but EBITDA guidance for next quarter missing analysts' expectations significantly.
Is Omnicell a buy or sell going into earnings? Read our full analysis here, it's free for active Edge members .
This quarter, the market is expecting Omnicell's revenue to decline 1.5% year on year, a reversal from the 10% increase it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Omnicell rarely misses Wall Street's revenue estimates.
With Omnicell being the first among its peers to report earnings this season, we don't have anywhere else to look to get a hint at how this quarter will unfold for healthcare technology stocks. However, there has been positive investor sentiment in the segment, with share prices up 3.6% on average over the last month. Omnicell is up 11.7% during the same time .
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal.Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you're unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE .
